Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on OECD Countries, 1995-2003

Health Economics

Volumn 18, Issue 5, 2009, Pages 519-534

  Lichtenberg, Frank R ^a,b  

^a Columbia University ^*  (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

Cardiovascular; Hospitalization; Innovation; Mortality; Pharmaceutical

Indexed keywords

AMLODIPINE; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; BISOPROLOL; CARDIOVASCULAR AGENT; CILAZAPRIL; DILTIAZEM; EZETIMIBE; FELODIPINE; FENOFIBRATE; FLUINDOSTATIN; FUROSEMIDE; GEMFIBROZIL; GLYCERYL TRINITRATE; HEPARIN; HERBACEOUS AGENT; HYDROCHLOROTHIAZIDE; IRBESARTAN; METOPROLOL; MEVINOLIN; NICOTINIC ACID; PERINDOPRIL; PRAVASTATIN; QUINAPRIL; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; TORASEMIDE; UNINDEXED DRUG;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; CRATAEGUS; DEMOGRAPHY; DRUG COST; DRUG MARKETING; DRUG UTILIZATION; EDUCATIONAL STATUS; GINKGO BILOBA; HEALTH CARE COST; HEALTH CARE DISTRIBUTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INCOME; LENGTH OF STAY; LONGITUDINAL STUDY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POPULATION SIZE; PRIORITY JOURNAL; PUBLIC HEALTH INSURANCE; RISK FACTOR; SMOKING;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DEVELOPED COUNTRIES; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES;

EID: 67149085958     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1382     Document Type: Article

References (22)

1. Aldonas GD. 2005. Pharmaceutical price controls in OECD countries, implications for American consumers, pricing, research and development, and innovation. Testimony of Under Secretary for International Trade, US Department of Commerce Before the Committee on Health, Education, Labor and Pensions, US Senate, Washington, DC, February 17, http://www.ita.doc.gov/media/Speeches/0205/aldonas_021705.html, accessed 10 January 2008.
2. Bahk B-H, Gort M. 1993. Decomposing learning by doing in new plants. Journal of Political Economy 101: 561-583.
3. Boucekkine R, de la Croix D, Licandro O. Vintage Capital, Department of Economics, European University Institute, Eco No. 2006/08. http://cadmus.iue.it/dspace/bitstream/1814/4346/1/ECO2006-8.pdf, accessed 10 January 2008.
4. Cannon CP et al. 2004. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine 350(15): 1495-1504.
5. Harrigan CJ, Appelbaum E, Maron BJ, Buros JL, Gibson CM, Lesser JR, Udelson JE, Manning WJ, Maron MS. 2008. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. American Journal of Cardiology 101(5): 668-673.
6. Hulten CR. 1992. Growth accounting when technical change is embodied in capital. The American Economic Review 82(4): 964-980.
7. IMS Health. 2006. IMS Retail Drug Monitor, Tracking 13 Key Global Pharma Markets, 12 months to December 2006, http://www.imshealth.com/ ims/portal/front/indexC/0,2773,6599_41382715_0,00.html, accessed 10 January 2008.
8. Kaiser Family Foundation. 2007. How Changes in Medical Technology Affect Health Care Costs, March, http://www.kff.org/insurance/ snapshot/chcm030807oth.cfm]front5, accessed 10 January 2008.
9. Lichtenberg F. 2001. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Affairs 20(5): 241-251.
10. Lichtenberg F. 2006a. The effect of using newer drugs on admissions of elderly Americans to hospitals and nursing homes: state-level evidence from 1997-2003. Pharmacoeconomics 24(Suppl 3): 5-25.
11. Lichtenberg F. 2006b. On 'new cardiovascular drugs: pattern of use and association with non-drug health expenditures'. Inquiry 43(1): 80-82.
12. Lichtenberg F. 2006c. The impact of increased utilization of HIV drugs on longevity and medical expenditure: an assessment based on aggregate US time-series data. Expert Review of Pharmacoeconomics and Outcomes Research 6(4): 425-436.
13. Lichtenberg F. 2007a. The impact of new drugs on US longevity and medical expenditure, 1990-2003: evidence from longitudinal, disease-level data. American Economic Review 97(2): 438-443.
14. Lichtenberg F. 2007b. Pharmaceutical innovation and U.S. cancer survival, 1992-2003: evidence from linked SEER-MEDSTAT data. Forum for Health Economics & Policy 10(1): 79 (Frontiers in Health Policy Research), Article 1. http://www.bepress.com/fhep/10/1/1.
15. Lichtenberg F. 2007c. Why has longevity increased more in some states than in others? The role of medical innovation and other factors. Manhattan Institute for Policy Research, Medical Progress Report No. 4, July, http://www.manhattan-institute.org/html/mpr_04.htm, accessed 10 January 2008.
16. Miller GE, Moeller JF, Stafford RS. 2005. New cardiovascular drugs: patterns of use and association with nondrug health expenditures. Inquiry 42(4): 397-412.
17. Popovic JR, Hall MJ. 2001. 1999 National Hospital Discharge Survey. Advance Data from Vital and Health Statistics, vol. 319. National Center for Health Statistics: Hyattsville, MD, http://www.cdc.gov/nchs/ data/ad/ad319.pdf, accessed 10 January 2008.
18. Rettig RA. 1994. Medical innovation duels cost containment. Health Affairs 13(3): 7-27.
19. Sakellaris P, Wilson D. 2004. Quantifying embodied technological change. Review of Economic Dynamics 7(1): 1-26.
20. Schmid M, Achenbach S, Ropers D, Komatsu S, Ropers U, Daniel WG, Pflederer T. 2008. Assessment of changes in non-calcified atherosclerotic plaque volume in the left main and left anterior descending coronary arteries over time by 64-slice computed tomography. American Journal of Cardiology 101(5): 579-584.
21. Weisfeldt ML, Zieman SJ. 2007. Advances in the prevention and treatment of cardiovascular disease. Health Affairs 26(1): 25-37.
22. Zhou Z, Rahme E, Pilote L. 2006. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. American Heart Journal 151(2): 273-281.